Cullinan Therapeutics, Inc.
CLN-978
SLE
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for CLN-978 in SLE are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In Q4 2026, the Company plans to share initial data from Part A (single target dose escalation) with a focus on safety and B cell depletion in peripheral blood and tissue, as well as other biomarker data and preliminary clinical activity da”